Close
Smartlab Europe
Inizio Ignite

Drug Research

Discover the Latest Information and Seize Market Opportunities in the Annual Event of the CRO & CMO Industry

As the pharmaceutical market demands in China continue to grow, China’s pharmaceutical policies become gradually clear, which provides broad space for the development of pharmaceutical enterprises. The CRO & CMO industry, an important part of the R&D industry chain...

IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets

IONTAS, a leader in the discovery and optimisation of fully human antibodies, announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells. The agreement is to generate and optimise...

BioMotiv and Atomwise Sign AI Partnership to Transform Therapeutic Development

BioMotiv, a mission-driven pharma company part of The Harrington Project for discovery and development, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, announced a strategic collaboration to co-develop therapies. The organizations will form co-owned,...

Astellas Announces Construction of New Manufacturing Facility for Active Pharmaceutical Ingredient of Prograf

The new manufacturing facility is designed to have advanced features based on the efficiency of the existing facilities and requires approximately JPY10bn ($90m) in construction costs Japanese pharmaceutical firm Astellas has unveiled plans to construct the Third Fermentation Building as...

CytoviaTherapeutics and the University of California enter into a partnership to develop precision gene-edited CAR-NK celltherapy

CytoviaTherapeutics,a biopharmaceutical company, and the University of California,San Francisco(UCSF) announced that they have entered a 3-year research partnership to develop novel precision gene editing to improve the performance, safety and persistence of Natural Killer(NK) cells and Chimeric Antigen Receptor(CAR)-NK...

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer...

BI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac Meets Primary and Secondary Endpoints

VBI Vaccines Inc. (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac®, the company’s trivalent hepatitis B (HBV) vaccine,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »